Lamivudine Solution
Product Images NDC 65862-055

Product Visual Gallery

This gallery contains 3 technical images submitted to the FDA as part of the official labeling for Lamivudine (NDC 65862-055). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1. Virologic Response Through Week 48, Epv20001a,b (intent-to-treat) (Lamivudine Figure1)

The text describes a figure showing the virologic response through week 48 for EPV200012. It presents the proportions of subjects with HIV-1 RNA less than 400 copies/mL for two treatments: Lamivudine 150 mg twice daily and Lamivudine 300 mg once daily. The figure is plotted over time, showing the treatment time in weeks on the X-axis and the proportion of subjects on the Y-axis. The figure has T and 0 symbols along the X-axis, indicating the time of assessment.*

FDA Label Image

Package Label-principal Display Panel -10 mg/ml (240 mL Bottle Label) (Lamivudine Figure2)

Each milliliter of the oral solution of Lamivudine USP manufactured by Aurobindo Pharma USA, Inc. contains 10 milligrams of Lamivudine USP. The usual dosage should be obtained from the package insert. This drug should be kept out of reach of children and stored at room temperature between 20-25°C (68° to 77°F) with allowed excursions to 15° to 30° (59° to 86°F). The code is TS/DRUGS/10/1993. The warning advises users to replace the cap securely after each 10 mg/mL opening. However, some text is not available.*

FDA Label Image

Chemical Structure (Lamivudine Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.